FIELD: medicine, pharmacy, chemical-pharmaceutical industry.
SUBSTANCE: invention relates to a preparation influencing on the immune system. Medicinal preparation comprises 5-amino-2,3-dihydro-1,4-phthalazinedione alkaline salt but lithium or potassium salt preferably. Preparations show anti-tumor and antioxidant effects. Method for producing the medicinal preparation involves preparing indicated salts by carrying out cycles for processing the parent compositions and treatment of intermediate compositions for preparing the end product and with repeated using mother liquors in indicated process after isolation of intermediate product and the end product from these solutions. The developed variants of medicinal preparation differ by duration and spectrum of effect and by pharmacokinetic indices, and depending on their purity degree, they can be used by oral intake, intramuscular injection and for other medicinal procedures. The proposed method for producing the preparation represents highly technological process of low-waste pharmaceutical manufacturing providing the preparing variants of the medicinal preparation.
EFFECT: improved preparing method.
35 cl, 4 dwg, 3 tbl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
MEDICINAL PREPARATION (VARIANTS) AND METHOD FOR ITS PRODUCTION | 2001 |
|
RU2211036C2 |
MEDICINAL PREPARATION (VARIANTS) | 2003 |
|
RU2302863C2 |
METHOD FOR PREPARING MEDICINAL PREPARATION | 2002 |
|
RU2222327C2 |
METHOD OF OBTAINING MEDICATION | 2010 |
|
RU2439063C1 |
METHOD OF OBTAINING ACTIVE PHARMACEUTICAL SUBSTANCE, PRESENTING AMINODIHYDROPHTHALAZINEDIONE OF SODIUM | 2017 |
|
RU2673452C1 |
EYE DROPS, EYE OINTMENT AND METHOD FOR TREATMENT OF OPHTHALMOLOGY DISEASES | 2003 |
|
RU2245138C1 |
INHALATION PREPARATION IN TREATMENT OF TUBERCULOSIS | 2003 |
|
RU2266119C2 |
METHOD OF PRODUCING O-LUMINOLATES OF ALKALI METALS | 2013 |
|
RU2532128C1 |
OINTMENT FOR TREATMENT OF AUTOIMMUNE DISEASES | 2003 |
|
RU2266118C2 |
PHARMACEUTICAL COMPOSITION WITH IMMUNOMODULATORY, IMMUNOCORRECTING, IMMUNOSUPPRESSIVE, ANTIVIRAL, ANTI-INFLAMMATORY AND ONCOLYTIC ACTIVITIES | 2021 |
|
RU2775008C1 |
Authors
Dates
2004-07-27—Published
2003-04-18—Filed